Antibody Conjugate Therapeutics: Challenges and Potential

Antibody conjugates are a diverse class of therapeutics consisting of a cytotoxic agent linked covalently to an antibody or antibody fragment directed toward a specific cell surface target expressed by tumor cells. The notion that antibodies directed toward targets on the surface of malignant cells could be used for drug delivery is not new.

The history of antibody conjugates is marked by hurdles that have been identified and overcome. Early conjugates used mouse antibodies; cytotoxic agents that were immunogenic (proteins), too toxic, or not sufficiently potent; and linkers that were not sufficiently stable in circulation.

  • Antibody-Drug Conjugates Design And Development
  • Bispecific antibody conjugates in therapeutics
  • Strategies and Advancement in Antibody-Drug Conjugate Optimization for Targeted Cancer Therapeutics
  • New Developments in Antibody-Drug Conjugates

Related Conference of Antibody Conjugate Therapeutics: Challenges and Potential

September 01-02, 2017

4th International Conference on Parasitology

Prague, Czech Republic
September 11-12, 2017

7th World Congress on Immunology

Amsterdam, Netherlands
November 2-3, 2017

9th World Congress and Expo on Immunology

Atlanta, Georgia, USA
November 02-03, 2017

9th World Congress on Immunity, Inflammation and Immunotherapies

Atlanta, Georgia, USA
November 06-07, 2017

2nd International Conference on Autoimmunity

Frankfurt, Germany
November 08-09, 2017

3rd Antibodies and Bio Therapeutics Congress & B2B

Las Vegas, Nevada, USA
November 13-14, 2017

5th International Conference on HIV/AIDS, STDs and STIs

Las Vegas, Nevada, USA
Dec 14-15, 2017

World Immunology Congress

Dubai, UAE

9th European Immunology Conference

June 14-16, 2018 Rome, Italy
July 05-07, 2018

EuroSciCon Conference on Immunology

Vienna, Austria

Antibody Conjugate Therapeutics: Challenges and Potential Conference Speakers

Recommended Sessions

Related Journals

Are you interested in